Company intelligence / Profile preview
Kaleido Biosciences
Bedford, Massachusetts, United Statesfda.gov ↗
- Ownership
- Private
- Employees
- ~82
- Development stage
- Phase 2
01
Overview
The company had Phase 2 clinical trials in urea cycle disorder, Phase 1 clinical trial in ulcerative colitis, and Phase 1/2 clinical trial in mild COVID-19 before shutting down in April 2022 due to cash constraints and drug setbacks.
- Therapeutic areas
- GastroenterologyCardiovascularMetabolic DisordersNephrologyEndocrinologyImmunologyDermatologyOncologyRare DiseasesInfectious Diseases
- Modalities
- Microbiome Metabolic Therapies (MMT)synthetic glycans
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Janssen (Johnson & Johnson subsidiary)CoreBiome
Beyond the preview
Go deeper on Kaleido Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kaleido Biosciences.